Back to search
FDAFDA · Food and drugs·Recall number D-1174-2023

SANDIMMUNE Oral Solution (cyclosporine oral solution, USP) 100 mg/mL, 50 mL bottle, Rx Only, Manufactured by: DELPHARM Huningue S.A.S., Huningue, France, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, NDC 0078-0110-22.

Published September 27, 2023 · Recall initiated: September 8, 2023

Summary

FDA records drug Class I recall D-1174-2023, published September 27, 2023 and initiated September 8, 2023. Recalling firm: Novartis Pharmaceuticals Corp.; Status: Ongoing; Reported quantity: 1272 bottles; Lot: FX001691, Exp. 12/31/2025. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Novartis Pharmaceuticals Corp.
Distributor
Nationwide in the USA
Lot
FX001691, Exp. 12/31/2025
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was SANDIMMUNE Oral Solution (cyclosporine oral solution, USP) 100 mg/mL, 50 mL bottle, Rx Only, Manufactured by: DELPHARM Huningue S.A.S., Huningue, France, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, NDC 0078-0110-22. recalled?

Yes. FDA published recall D-1174-2023 on September 27, 2023. Reported hazard: Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals.

What should I do if I have this product?

Voluntary: Firm initiated · Letter